EU regulator added thrombosis information to AstraZeneca description
The European Medicines Agency has added information about the possible development of thrombosis in the description of the AstraZeneca coronavirus vaccine. RIA Novosti writes about this with reference to the EMA document.
“The combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, in very rare cases was observed after vaccination with the drug,” the document says.
Now, vaccineers must inform patients about possible side effects, as well as instruct patients on how to behave if vaccinated if they develop symptoms of thrombosis, that is, shortness of breath, chest or abdominal pain, leg swelling, severe and persistent headaches, and deterioration of vision.
Earlier it was reported that the developers of the British-Swedish vaccine against the coronavirus AstraZeneca began researching why blood clots form in some patients after being vaccinated with the drug.
On April 7, the British Medicines and Medical Devices Regulatory Agency reported that 79 cases of blood clots were recorded in the country in those vaccinated with the AstraZeneca coronavirus vaccine. The regulator also discouraged the use of the AstraZeneca vaccine for individuals under 30 years of age due to the growing body of evidence linking the vaccine to blood clots.
Later, the WHO called a possible connection between AstraZeneca and thrombosis. The WHO stressed that the described cases are of concern, but they are extremely rare: among the almost 200 million vaccinated, isolated cases were recorded.